At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AMGN Amgen
Pre-Mkt 08-07 06:52:31 EDT
404.85
-2.98
-0.73%
盘前404.00
-0.85-0.21%
06:45 EDT
High418.40Low401.20Vol2.61M
Open413.72D1 Closing407.83Amplitude4.22%
Mkt Cap218.00BTradable Cap217.40BTotal Shares538.48M
T/O1.06BT/O Rate0.49%Tradable Shares536.99M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Sino Biopharmaceutical Stock Climbs 3.3% in Hong Kong, Outperforms Competitors
Dow Jones  ·  16:30
Sino Biopharmaceutical Stock Climbs 3.3% in Hong Kong, Outperforms Competitors
Amgen Price Target Raised to $345.00/Share from $335.00 by Bernstein
Dow Jones  ·  00:43
Amgen Price Target Raised to $345.00/Share from $335.00 by Bernstein
Salesforce, UnitedHealth Share Losses Contribute to Dow's Nearly 150-Point Drop
Dow Jones  ·  08-06 22:46
Salesforce, UnitedHealth Share Losses Contribute to Dow's Nearly 150-Point Drop
Rothschild & Co Redburn Adjusts Amgen Price Target to $235 From $220, Maintains Sell Rating
MT Newswires Live  ·  08-06 21:43
Rothschild & Co Redburn Adjusts Amgen Price Target to $235 From $220, Maintains Sell Rating
Bernstein Reaffirms Their Hold Rating on Amgen (AMGN)
TIPRANKS  ·  08-06 19:59
Bernstein Reaffirms Their Hold Rating on Amgen (AMGN)
Generate Biomedicines Q2 FY26 Net Loss Widens to $67.26 Million; Revenue Drops to $6.31 Million
Reuters  ·  08-06 18:11
Generate Biomedicines Q2 FY26 Net Loss Widens to $67.26 Million; Revenue Drops to $6.31 Million
Exelixis Q2 Revenue Misses Analyst Estimates, Lowers 2026 Outlook
Reuters  ·  08-06 04:53
Exelixis Q2 Revenue Misses Analyst Estimates, Lowers 2026 Outlook
Amgen Inc. Stock Climbs 4.6%, Outperforms Peers
Dow Jones  ·  08-06 04:35
Amgen Inc. Stock Climbs 4.6%, Outperforms Peers
Vir Biotechnology Q2 Revenue Up, Beats Estimates on Astellas Payment
Reuters  ·  08-06 04:20
Vir Biotechnology Q2 Revenue Up, Beats Estimates on Astellas Payment
Amgen is Maintained at Equal-Weight by Wells Fargo
Dow Jones  ·  08-05 23:03
Amgen is Maintained at Equal-Weight by Wells Fargo
NASDAQ Top and Bottom Performing Stocks at About 11:01 A.m. EDT on 2026-08-05
Reuters  ·  08-05 23:01
NASDAQ Top and Bottom Performing Stocks at About 11:01 A.m. EDT on 2026-08-05
Wall Street Warms to Healthcare Stocks as Tech Trade Faces Turbulence
Reuters  ·  08-05 22:45
Wall Street Warms to Healthcare Stocks as Tech Trade Faces Turbulence
Amgen Jolts to Record-High After Hiking FY Forecasts, Q2 Results Beat
Reuters  ·  08-05 22:40
Amgen Jolts to Record-High After Hiking FY Forecasts, Q2 Results Beat
Amgen Shares Hit Record High; Last up 6.3% at $414.61
THOMSON REUTERS  ·  08-05 22:09
Amgen Shares Hit Record High; Last up 6.3% at $414.61
Amgen price target raised to $440 from $420 at UBS
TIPRANKS  ·  08-05 22:01
Amgen price target raised to $440 from $420 at UBS
Amgen Shares up 5% After Q2 Results Beat Estimates; FY Profit Forecast Raise
THOMSON REUTERS  ·  08-05 21:55
Amgen Shares up 5% After Q2 Results Beat Estimates; FY Profit Forecast Raise
Dow's 500-Point Rally Led by Gains in Amgen, Nvidia Corp. Shares
Dow Jones  ·  08-05 21:45
Dow's 500-Point Rally Led by Gains in Amgen, Nvidia Corp. Shares
Movement Alert｜Amgen Rises 4.2% in Regular Trading, Q2 Earnings Significantly Beat Expectations with Raised Full-Year Guidance
Market Focus  ·  08-05 21:43
Movement Alert｜Amgen Rises 4.2% in Regular Trading, Q2 Earnings Significantly Beat Expectations with Raised Full-Year Guidance
Amgen Inc : Canaccord Genuity Raises Target Price to $384 from $366
THOMSON REUTERS  ·  08-05 21:14
Amgen Inc : Canaccord Genuity Raises Target Price to $384 from $366
Immuneering Expects Cash Runway to Fund Operations into 2029
Reuters  ·  08-05 19:40
Immuneering Expects Cash Runway to Fund Operations into 2029

Introduction

Company Name.
Amgen
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
Issue price:
--